Clinical trials: Phase I
Pharmacokinetic Variables
Assessment of the Effect of Food on ABT-143 Bioavailability
Single-dose, open-label, two-period crossover study of ABT-143
- Trial name
- NCT00719693
- Testing
- ABT-143 ( rosuvastatin calcium and fenofibric acid ), ABT-143 (rosuvastatin calcium and fenofibric acid )
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers
The purpose of this study is to further study the pharmacokinetic characteristics of Chiauranib Capsule in Healthy Volunteers with High Fat Diet.
- Trial name
- NCT05346601
- Testing
- Chiauranib
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Asthma COPD
Single and Multiple Ascending Dose Study of KN-002
This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 4 parts: Part 1 is a single ascending dose (SAD) study in healthy volunteers; Part 2 is a multiple ascending dose (MAD) study in…
- Trial name
- KN-002 (NCT05006521)
- Testing
- KN-002
- Where
- United Kingdom
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Kinaset Therapeutics Inc
Healthy Volunteers
A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.
The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin
- Trial name
- NCT07567781
- Testing
- ABBV-722, Midazolam, Metformin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AbbVie
Covid19
Anti-COVID19 AKS-452 Fusion Protein Vaccine - ACT Study
Combinatorial phase I/II safety, tolerability and immunogenicity single center open-label clinical study of AKS-452 COVID-19 vaccination study
- Trial name
- ACT (NCT04681092)
- Testing
- AKS-452
- Where
- Netherlands
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
COVID-19, SARS-CoV-2 Infection
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.
The objective of this study is to evaluate the safety, tolerability and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with mRNA COVID-19 vaccine.
- Trial name
- NCT05043311
- Testing
- SCTV01C
- Where
- United Arab Emirates
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
SARS-CoV-2
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults.
This is a phase I, randomized, observer-blinded, placebo-controlled and dose-escalation clinical trial to evaluate the safety and preliminary immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese healthy adults aged 60…
- Trial name
- NCT05354063
- Testing
- 20 μg dose of SYS6006, 30 μg dose of SYS6006
- Where
- 2 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Volunteers
A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants
The primary purpose of this study is to characterize and compare the pharmacokinetic profiles of mitapivat following a single dose administration of 100 mg mitapivat in two tablet formulations (50 mg and 100 mg tablet strengths)…
- Trial name
- NCT04696393
- Testing
- Mitapivat tablet
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Agios Pharmaceuticals, Inc.
Influenza
Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults
It is the hypothesis of this study that intranasal vaccination with a single dose of GHB04L1 is safe and induces an immune response against influenza A H5N1.
- Trial name
- GHB-CS03 (NCT00741806)
- Testing
- GHB04L1
- Where
- Austria
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AVIR Green Hills Biotechnology AG
COPD
Pharmacokinetics and Safety Study of PT010 in Healthy Subjects
This is a single-center, Phase I, healthy adult subject study with a randomized, double blind, three period, three-treatment, cross-over design.
- Trial name
- NCT02189304
- Testing
- PT010, PT009, Symbicort Turbohaler
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Pearl Therapeutics, Inc.
Healthy Volunteer
A Phase I Study of TS-142 in Healthy Participants (Repeated Doses)
The purpose of this study is to investigate the safety, pharmacokinetics, and pharmacodynamics of repeated dosing of TS-142 when administered once daily to healthy Japanese non-elderly participants.
- Trial name
- NCT04169906
- Testing
- TS-142, 10 mg, TS-142, 20 mg, TS-142, 30 mg
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Malaria
Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)
Background: The malaria vaccine Pfs25-EPA/Alhydrogel may help block malaria parasites from developing in mosquitoes. When a mosquito bites a vaccinated person, the vaccine should prevent parasites from developing in the mosquito.
- Trial name
- NCT01434381
- Testing
- Pfs25-EPA/Alhydrogel
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
A Safety and Immune Response Study of 2 Experimental HIV Vaccines
The HIV Vaccine Trials Network (HVTN) is doing a study to test a new HIV vaccine combination. HIV is the virus that causes AIDS. 252 people are taking part in this study at multiple sites.
- Trial name
- NCT02404311
- Testing
- ALVAC-HIV, Bivalent Subtype C gp120/MF59®
- Where
- 5 sites in South Africa
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe Substrate for Cytochrome P450 3A4)
The main purpose of this study is to evaluate the effect of steady-state concentrations of JNJ-56136379 on the single-dose pharmacokinetics (PK) of drospirenone and ethinylestradiol (oral contraceptive [OC]) in healthy female…
- Trial name
- NCT03111511
- Testing
- Drospirenone/Ethinylestradiol, Midazolam, JNJ-56136379
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Janssen Sciences Ireland UC
Influenza
H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults
The purpose of this study is to compare how the body reacts to different strengths of the new A/H5N1 flu vaccine when given with the addition of aluminum hydroxide adjuvant and provide dosing information.
- Trial name
- NCT00294099
- Testing
- Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
- Where
- 7 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
A Study to Evaluate the Pharmacokinetics of Oral Formulations of MMV390048 Administered Fasted to Healthy Volunteers
This study will be conducted in a single centre, as an open single dose two parallel cohorts design with oral doses of MMV390048 administered in healthy male and female subjects between 18 to 55 years of age.
- Trial name
- NCT02554799
- Testing
- MMV390048 formulation A, MMV390048 formulation B
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Healthy Volunteers
A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects
This is a Phase 1, 2-part double-blinded (with respect to NX-5948/placebo), placebo-controlled study. Part 1 is a randomized, 3 period cross-over food-effect (FE) and drug-drug interaction (DDI) study.
- Trial name
- NCT06593457
- Testing
- IP
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Nurix Therapeutics, Inc.
Healthy
Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241
The aims of the study are to assess the safety, tolerability and pharmacokinetics of ER tablets of AZD3241 following multiple ascending doses administered to healthy male and female subjects including the effect of food.
- Trial name
- NCT00914303
- Testing
- AZD3241
- Where
- Sweden
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Subjects, Pharmacokinetics of ASP6294
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects
The purpose of this study is to evaluate the safety and tolerability of single ascending intravenous doses and single subcutaneous (sc) doses of ASP6294 in healthy young male and female subjects.
- Trial name
- NCT02681861
- Testing
- ASP6294 Intravenous, ASP6294 Subcutaneous
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy, Atopic Dermatitis
A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis
The clinical study consists of three parts: Part 1 with healthy volunteers. Part 2 and Part 3 including subjects with moderate to severe atopic dermatitis (a skin disease).
- Trial name
- NCT03689829
- Testing
- MOR106
- Where
- 15 sites in Germany, Spain and 2 more
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.